Evaluation of minimal residual disease in relapsed/refractory multiple myeloma patients treated with venetoclax or placebo in combination with bortezomib and dexamethasone: BELLINI study analyses.

 

Abstract No : 8547

Abstract Type : Poster Discussion Session

Indication : Multiple Myeloma

Intervention : Venetoclax

Company : AbbVie and Genentech

Technology : Small molecule

 

Results:

In total, 291 pts were randomized; 194 to Ven, 97 to Pbo. As of 13 Sep 2019, the median follow-up was 29 months. Ven + Bd demonstrated significantly higher MRD negativity rates (< 10−5), including a higher proportion of pts achieving sustained MRD negativity (Table). In the Ven arm, the median (m)PFS was not reached for MRD negative pts vs 16.2 months for MRD positive pts (HR = 0.23, 95% CI: 0.10-0.54, p < 0.001). While the mOS was not reached in the Ven arm, OS was significantly longer for MRD negative vs MRD positive pts (HR = 0.25, 95% CI: 0.08-0.80, p = 0.0194).

 

Conclusion:

The addition of Ven to Bd resulted in deep and durable responses, including higher rates of MRD negativity. MRD negativity in the context of Ven was associated with prolonged survival in patients with RRMM, consistent with the broader MRD body of evidence with other therapies in MM.

 

Commentary:

Venetoclax + Bd has proved to be quite effective as compared to Bd alone to achieve a higher rate of

Note: The therapeutics segment is experiencing significant Multiple Myeloma clinical trial activity, which is further expected to drive Multiple Myeloma market growth in the coming years.